MedPath

Response and Clearance of Viral DNA Following Administration of Live Attenuated Varicella Vaccine.

Withdrawn
Conditions
Varicella
Transplants
Registration Number
NCT02692066
Lead Sponsor
University of Colorado, Denver
Brief Summary

Varicella zoster virus (VZV) can lead to significant morbidity and mortality in transplant recipients. Current recommendations suggest a 4 week waiting period between vaccination and transplantation and consideration of booster immunizations if antibody response does not reach target levels. This four week waiting period can result in delayed transplant, rejection of an optimal organ, or missed opportunity to vaccinate. However, these recommendations are not evidence based.

This is a prospective study to look at the immune response to varicella vaccine in children with chronic liver disease.

Investigators will evaluate:

1. the time at which VZV DNA becomes undetectable in blood and saliva by PCR after vaccination in children with chronic liver disease and

2. the difference in humoral and cell mediated immune response to varicella immunization between children with chronic liver disease and healthy children.

Detailed Description

Not available

Recruitment & Eligibility

Status
WITHDRAWN
Sex
All
Target Recruitment
Not specified
Inclusion Criteria
  • 6 months to 21 years
  • no history of varicella, zoster or prior varicella vaccination
Exclusion Criteria
  • acute liver failure
  • liver transplant anticipated within 28 days
  • prior history of receiving blood products or immunoglobulin within 5 months prior to vaccination
  • fever
  • pregnancy
  • immunocompromised status
  • receiving immunosuppressive meds

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
clearance of viral DNA4 weeks
humoral response4 weeks
cell mediated response4 weeks
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.